Vivos Therapeutics, Inc., a company specializing in medical devices and therapies, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-3, initially filed on July 30, 2024. The company seeks to have the registration become effective at 4:30 p.m. on August 7, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Additionally, Vivos Therapeutics has authorized Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP to communicate with the SEC staff regarding any potential deferral of the new effective time.

Vivos Therapeutics, Inc., a company specializing in medical devices and therapies, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-3, initially filed on July 30, 2024. The company seeks to have the registration become effective at 4:30 p.m. on August 7, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Additionally, Vivos Therapeutics has authorized Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP to communicate with the SEC staff regarding any potential deferral of the new effective time.